



## DRUG QUANTITY MANAGEMENT POLICY – PER RX

- POLICY:** Oncology – Imbruvica Drug Quantity Management Policy – Per Rx
- Imbruvica® (ibrutinib tablets, capsules, and oral suspension – Pharmacyclics/Janssen)

**REVIEW DATE:** 07/12/2023

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

### **CIGNA NATIONAL FORMULARY COVERAGE:**

#### **OVERVIEW**

Imbruvica, a Bruton's tyrosine kinase inhibitor, is indicated for the following:<sup>1</sup>

- **Chronic lymphocytic leukemia (CLL)** or **small lymphocytic lymphoma (SLL)**, in adults.
- **CLL** or **SLL**, with 17p deletion, in adults.
- **Graft-versus-host disease, chronic**, in adults and pediatric patients  $\geq 1$  year of age after failure of one or more lines of systemic therapy.
- **Waldenström macroglobulinemia**, in adults.

#### **Dosing**

For CLL, SLL, and Waldenström macroglobulinemia, the recommended dose of Imbruvica is 420 mg once daily (QD) until disease progression or unacceptable toxicity.<sup>1</sup> It can be administered as a single-agent or in combination with other agents.

For chronic graft-versus-host disease  $\geq 12$  years of age, the recommended dose of Imbruvica is 420 mg QD. For patients 1 to  $< 12$  years of age, the recommended dose is 240 mg/m<sup>2</sup> QD (up to 420 mg QD), until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity.

To manage adverse events, dose reductions/modifications to 280 mg QD or 140 mg QD may be needed for patients  $\geq 12$  years of age.<sup>1</sup> For patients 1 to  $< 12$  years of age, modifications to 160 mg/m<sup>2</sup> or 80 mg/m<sup>2</sup> are recommended (potential doses are 70 mg, 140 mg, 210 mg, 280 mg QD using either the tablets or oral suspension). Similarly, dose reductions may be needed to manage drug interactions, as well as hepatic impairment.

**Availability**

Imbruvica is available as a 70 mg and 140 mg capsules and 140 mg, 280 mg, and 420 mg tablets. Imbruvica is also supplied as a 70 mg/mL oral suspension in bottles containing 108 mL each.

**Off-Label Dosing**

Guidelines also support the use of Imbruvica for central nervous system lymphoma, hairy cell leukemia, mantle cell lymphoma, marginal zone lymphoma, and other B-cell lymphomas.<sup>2-5</sup> The recommended dose for mantle cell lymphoma, marginal zone lymphoma, and other B-cell lymphomas is 560 mg QD.<sup>2</sup> Dosing used for central nervous system lymphoma is up to 560 mg or 840 mg QD.<sup>4,6-8</sup> A dose of 420 mg QD is recommended for hairy cell leukemia.<sup>5</sup>

**POLICY STATEMENT**

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Imbruvica. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

**Drug Quantity Limits**

Product	Strength and Form	Retail Maximum Quantity per Rx	Home Delivery Maximum Quantity per Rx
Imbruvica® (ibrutinib capsules, tablets and oral suspension)	70 mg capsules	30 capsules	90 capsules
	140 mg capsules	120 capsules	360 capsules
	140 mg tablets	30 tablets	90 tablets
	280 mg tablets	30 tablets	90 tablets
	420 mg tablets	30 tablets	90 tablets
	70 mg/mL oral suspension* (108 mL per bottle)	324 mL	972 mL

\* Quantity limits for the Imbruvica oral suspension allow for a dose of 560 mg once daily, rounded up to the nearest bottle size; exceptions are provided for patients who require doses of 840 mg once daily.

**Oncology – Imbruvica Drug Quantity Management Policy – Per Rx product(s) is(are) covered as medically necessary when the following**

**criteria is(are) met. Any other exception is considered not medically necessary.**

### **CRITERIA**

#### Imbruvica 70 mg capsules

1. If a patient requires a dose of 210 mg once daily, approve 90 capsules per dispensing at retail or 270 capsules per dispensing at home delivery.

#### Imbruvica 140 mg capsules

No exceptions.

#### Imbruvica 140 mg tablets

No exceptions.

#### Imbruvica 280 mg tablets

1. If the patient requires a dose of 560 mg once daily to treat central nervous system lymphoma, mantle cell lymphoma, marginal zone lymphoma, or other B-cell lymphomas, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

Note: Other B-cell lymphomas include diffuse large B-cell lymphomas, Acquired Immune Deficiency Syndrome (AIDS)-related B-cell lymphomas, post-transplant lymphoproliferative disorders, double/triple hit lymphoma, and high-grade B-cell lymphoma.

#### Imbruvica 420 mg tablets

1. If the patient requires a dose of 840 mg once daily to treat central nervous system lymphoma, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

#### Imbruvica 70 mg/mL oral suspension

1. If the patient requires a dose of 840 mg once daily to treat central nervous system lymphoma, approve 432 mL per dispensing at retail or 1,080 mL per dispensing at home delivery.

### **REFERENCES**

1. Imbruvica® tablets, capsules, and oral solution [prescribing information]. Sunnyvale, CA and Horsham, PA: Pharmacyclics/Janssen; May 2023.
2. The NCCN B-Cell Lymphomas Guidelines in Oncology (version 4.2023 – June 2, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 6, 2023.
3. The NCCN Drugs and Biologics Compendium. © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 6, 2023. Search term: ibrutinib.
4. The NCCN Central Nervous System Cancers Guidelines in Oncology (version 1.2023 – March 24, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 6, 2023.
5. The NCCN Hairy Cell Leukemia Guidelines in Oncology (version 1.2023 – August 30, 2022). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 6, 2023.

6. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. *Cancer Discov.* 2017;7:1018-1029.
7. Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib based combination therapy in recurrent/refractory CNS lymphoma. *Blood.* 2019;133:436-445.
8. Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. *Eur J Cancer.* 2019;117:121-130.

## HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	New policy created to provide exceptions to previously existing quantity limits.	07/12/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna